Compass therapeutics presents novel biomarker data related to ctx-471 clinical activity at the 39th society for immunotherapy of cancer (sitc) annual meeting

Boston, nov. 08, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “pharmacodynamic and response biomarkers in the monotherapy arm of a phase 1 trial of ctx-471, a novel anti-cd137 agonist antibody” at the 39th society for immunotherapy of cancer (sitc) annual meeting, from november 6-10, 2024 in houston, tx.
CMPX Ratings Summary
CMPX Quant Ranking